Dupilumab SAR231893
LPS16764
Approved small_molecule completed
Quick answer
Dupilumab SAR231893 for Dermatitis Atopic is a Approved program (small_molecule) at Regeneron UK Limited with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Regeneron UK Limited
- Indication
- Dermatitis Atopic
- Phase
- Approved
- Modality
- small_molecule
- Status
- completed